Please provide your email address to receive an email when new articles are posted on . Predicting treatment risk using geriatric assessment and genetic profiling for AML may impact early rates of ...
Despite advanced age, some patients are able to withstand aggressive, curative treatment for AML. We have developed online assessment tools that help predict the best course of treatment for older, ...
Measurable residual disease (MRD) assessment plays a critical role in monitoring acute myeloid leukemia (AML) progression and relapse risk. Current standard-of-care approaches, including ...
Add to Calendar: Add to Calendar: 2021-09-23 19:00:00 2021-09-23 20:00:00 Integrating a Risk Assessment into an AML Program Event Description The FATF recommendations and regulators encourage ...
Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty ...
GlobalData has released its pharmaceutical report, "Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on ...
Flow MRD, also offering a high sensitivity (up to 10 −4), is applicable in >90% of all cases. 7, 9, 12 The basis of flow MRD is the definition and detection of leukemia-associated aberrant ...
Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results